Efficacy and Safety of Oral Conivaptan: A V1A/V2Vasopressin Receptor Antagonist, Assessed in a Randomized, Placebo-Controlled Trial in Patients with Euvolemic or Hypervolemic Hyponatremia | Zendy

Jalal K. Ghali | Zendy; Michael J. Koren | Zendy; James R. Taylor | Zendy; Esther M. Brooks-Asplund | Zendy; Kaisheng Fan | Zendy; Walker Long | Zendy; Neila Smith | Zendy

Open Access

Efficacy and Safety of Oral Conivaptan: A V_1A/V₂Vasopressin Receptor Antagonist, Assessed in a Randomized, Placebo-Controlled Trial in Patients with Euvolemic or Hypervolemic Hyponatremia

Author(s) -

Jalal K. Ghali,

Michael J. Koren,

James R. Taylor,

Esther M. Brooks-Asplund,

Kaisheng Fan,

Walker Long,

Neila Smith

Publication year - 2006

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2005-2287

Subject(s) - hyponatremia , antagonist , medicine , placebo , tolvaptan , vasopressin , receptor antagonist , randomized controlled trial , vasopressin receptor , anesthesia , pharmacology , receptor , alternative medicine , pathology

Hyponatremia [serum sodium concentration ([Na(+)]), <135 mEq/liter] is the most common fluid and electrolyte abnormality among hospitalized patients. It is frequently caused by the inappropriate release of arginine vasopressin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research